Participants in this study must have been diagnosed with Type 1 Diabetes within 8 weeks before starting the study medication. They must also have certain antibodies in their blood that are related to Type 1 Diabetes, such as antibodies against glutamic acid decarboxylase, insulinoma antigen-2, zinc-transporter 8, insulin, or islet cell cytoplasmic autoantibodies. Antibodies are proteins made by the immune system that can sometimes attack the body’s own tissues. The study will also measure C-peptide, which is a substance that shows how much insulin the body is still making on its own. Participants need to have a certain level of C-peptide to be eligible for the study.

During the study, doctors will check several things to see how well the treatment is working. They will measure glycated hemoglobin, also called HbA1c, which shows average blood sugar levels over time. They will count how many days participants can go without needing insulin at mealtimes. They will also use a mixed meal tolerance test to measure C-peptide levels after participants eat a standard meal. The study will use continuous glucose monitoring to track blood sugar levels throughout the day and night. Doctors will watch for low blood sugar events, which are called hypoglycemic events, and will check for any side effects or unwanted reactions to the medication. They will also measure the amount of teplizumab in the blood and check if the body develops antidrug-antibodies, which are immune responses against the medication.

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the VX-264 Implant in people with Type 1 Diabetes. Participants in the study will receive the implant, and researchers will monitor how well it works and how the body responds to it. The study will be conducted in different parts, with each part focusing on different aspects of the treatment, such as safety and how well it helps the body produce insulin.

Throughout the study, participants will undergo various assessments to ensure their safety and to measure the treatment’s effects. These assessments may include checking vital signs, conducting imaging tests like MRI or ultrasound, and evaluating blood sugar levels. The study aims to provide valuable information about the potential of the VX-264 Implant as a treatment option for people with Type 1 Diabetes.

The purpose of this study is to see if these diabetes medications can help stabilize or reduce the buildup of plaque in the heart’s blood vessels after a heart attack in people with diabetes. During the study, participants will take one of these medications for 12 months. The study will use a special imaging test called coronary CT angiography, which is a type of scan that takes detailed pictures of the blood vessels in the heart. This scan will be done at the beginning of the study and again after 12 months to measure any changes in the amount of plaque in the blood vessels. The main focus will be on blood vessels that were not treated during the procedure to open blocked arteries, which is called PCI or percutaneous coronary intervention.

Throughout the study, doctors will also look at other health markers including substances in the blood that show inflammation, markers that indicate how well blood sugar is controlled, and features of the plaque that might indicate higher risk. They will also check how well any treated blood vessels are healing and whether participants are taking their medication as prescribed. The study will last for approximately 12 months of treatment for each participant.

The purpose of this study is to see if semaglutide can reduce inflammation inside the plaques that build up in the heart arteries. Inflammation is a process where the body’s immune system responds to damage or disease, and in this case, certain immune cells called macrophages collect in the plaques. The study will measure whether the medication can decrease the amount of these macrophages in the plaques. To do this, doctors will use a special imaging technique called optical coherence tomography, which is a way of taking detailed pictures of the inside of the arteries using light waves. This procedure allows doctors to see the structure and composition of the plaques.

During the study, participants will receive either semaglutide or a placebo for 24 weeks. At the beginning and end of this period, doctors will perform optical coherence tomography to examine the plaques in the arteries that are not the main blocked artery that caused the heart problem. The study will look at various features of these plaques, including their size, thickness of the covering layer, and the presence of different materials like fat and calcium. Doctors will also monitor blood sugar control, body weight, any heart-related events, and any side effects that may occur during the treatment period.

The purpose of this study is to find out how these hormone medications affect blood sugar control in women with diabetes who are experiencing menopause symptoms. The study will look at whether using estradiol patches combined with progesterone capsules helps to keep blood sugar levels within a healthy range. During the study, participants will have periods where they receive the hormone treatment and periods where they do not receive treatment. Blood sugar levels will be measured continuously using a monitoring device worn on the body for two weeks at different times during the study.

The study will also look at other health measures, including how well insulin works in the body, changes in blood pressure, cholesterol levels, liver fat content, muscle strength, and various symptoms related to menopause and diabetes. Participants will complete questionnaires about their symptoms, sleep quality, mood, and overall quality of life. Some participants will undergo additional tests such as an MRI scan to measure liver fat and specialized tests to measure how the body responds to insulin. The entire treatment period will last up to 60 months, during which participants will be monitored to see how the hormone treatment affects their diabetes control and overall health.

The main purpose of this study is to evaluate if this new treatment is safe for patients who have been recently diagnosed with Type 1 diabetes and still have some functioning insulin-producing cells. The treatment is given as a single intravenous injection of the modified cells back into the patient’s body.

During the study, patients will be monitored closely for any side effects and changes in their diabetes condition. The monitoring includes regular blood tests, checking blood sugar levels, and measuring how well the body is producing insulin. The study will track how the modified cells perform in the body and observe any changes in the patient’s need for insulin treatment over time.

Participants in the study will use a device called Continuous Glucose Monitoring (CGM) to track their blood sugar levels. This device helps to provide a detailed picture of how blood sugar changes throughout the day and night. The study will last for several months, during which time participants will have their blood sugar levels closely monitored. The goal is to see if the higher dose of insulin glargine helps keep blood sugar levels within a healthy range more effectively than the lower dose.

Throughout the study, researchers will also keep an eye on any side effects or health issues that might arise from the change in insulin dosage. This includes monitoring for episodes of low blood sugar, known as hypoglycemia, and any other adverse events. The study aims to provide valuable information on whether the higher dose of insulin glargine is a better option for managing blood sugar in people with Type 2 Diabetes and kidney problems.

The study tests whether allopurinol, a medication that lowers uric acid levels in the blood, can help reduce the risk of cardiovascular events. Some participants will receive allopurinol tablets, while others will receive a placebo. The treatment will continue for approximately 5 years, during which participants will have regular check-ups to monitor their health status.

The main focus is to determine if allopurinol can prevent serious cardiovascular events such as heart problems, strokes, or the need for heart-related procedures. The study will also track other health changes, including heart function, blood vessel health, and the presence of long-COVID symptoms. Regular blood tests and heart examinations will be performed to monitor participants’ health throughout the study period.

The study will compare two groups of participants over three years. One group will receive metformin treatment, while the other group will receive standard care without metformin. The medication will be taken by mouth, with a maximum daily dose of 1700 mg. Participants will have regular check-ups to monitor their health status throughout the study period.

During the study, various health measurements will be taken, including blood sugar levels, weight changes, and overall health status. The research will also look at how the treatment affects quality of life and examine changes in digestive system bacteria. This information will help understand the long-term benefits of using metformin after weight loss surgery to prevent diabetes from returning.

The purpose of the study is to evaluate how safe and effective the VX-880 treatment is for these patients. Participants in the study will receive the treatment through a process called infusion, where the solution is delivered directly into the body. The study will monitor participants over time to see how well they tolerate the treatment and whether it helps them manage their diabetes better. This includes checking if they can reduce or stop using insulin and if they experience fewer episodes of severe low blood sugar.

Throughout the study, participants will be closely observed to ensure their safety and to track any changes in their health. The study aims to provide valuable information on whether VX-880 can be a beneficial treatment option for people with Type 1 Diabetes who struggle with severe low blood sugar and impaired awareness of these episodes.

Participants in the study will receive either denosumab or a placebo through an intravenous infusion. The study will last for about nine months, during which time the participants’ foot health will be monitored using X-rays and CT scans. These scans will help doctors see how well the bones are healing. The study will also look at other factors, such as changes in foot shape and temperature, to understand the overall impact of the treatment.

The purpose of this study is to determine if denosumab can provide beneficial effects for people with Charcot foot due to diabetes. By understanding how this medication works in these patients, researchers hope to find better ways to manage and treat this challenging condition.

The purpose of the study is to determine whether HBOT is effective in treating these ulcers and to find out the best number of therapy sessions needed to achieve the desired effect. Participants in the study will receive either the oxygen treatment or a placebo, and their progress will be monitored over a period of time. The study will look at the rate of major amputations after 12 months to assess the effectiveness of the treatment.

During the study, participants will undergo regular assessments to monitor their condition and the healing of their ulcers. The treatment involves inhaling Oxygen as a medicinal gas, either in a cryogenic or compressed form, through inhalation. The study aims to provide valuable information on whether adding HBOT to standard care can improve outcomes for patients with diabetic ulcers.

The study will compare denosumab with placebo to determine its effectiveness. Participants will receive either 60 mg of denosumab or saline solution (salt water) injections. The purpose of this research is to evaluate how denosumab influences muscle mass, strength, and how well the body processes insulin in postmenopausal women who have both diabetes and bone health concerns.

The treatment period will last for 12 months, during which various measurements will be taken to track changes in muscle strength and the body’s response to insulin. Throughout the study, participants will undergo regular check-ups to monitor their progress and any changes in their condition. The study will measure several factors related to bone health, muscle function, and blood sugar control to better understand how the medication works.

The purpose of the study is to understand how these medications differ in their positive effects on fat tissue function. Fat tissue, also known as adipose tissue, plays a crucial role in storing energy and regulating hormones. The study will explore how these medications might improve the way fat tissue works in people with Type 2 Diabetes. Participants will be randomly assigned to receive one of the medications or a placebo, and the study will last for a period of six months.

Throughout the study, participants will take their assigned medication daily and attend regular check-ups to monitor their health and the effects of the medication. The study aims to provide valuable insights into how these medications can benefit people with Type 2 Diabetes by improving the function of their fat tissue. This research could lead to better treatment options and improved quality of life for those living with this condition.

The purpose of the study is to investigate how Alendronate affects markers related to bone health and blood sugar control in patients with diabetes. Participants will take the medication in the form of tablets, and the study will monitor changes in their bone and blood sugar markers over time. The study will last for a period of up to 24 months, during which participants will have regular check-ups to assess their health and the effects of the treatment.

Throughout the study, various health indicators will be measured, including HbA1c (a marker of blood sugar levels), bone density, and other substances in the blood that can provide information about bone and metabolic health. The study aims to provide insights into how Alendronate can benefit patients with diabetes who also have concerns about their bone health.

Participants in the study will receive Ozempic as a solution for injection, which is administered using a pre-filled pen. The study will compare different doses of Ozempic (0.25 mg, 0.5 mg, and 1 mg) to see how they influence blood sugar control. Some participants may receive a placebo, which is a treatment that looks like the real medication but does not contain the active substance. The study will last for about six months, during which time participants will be monitored to see how their blood sugar levels change.

Throughout the study, researchers will also look at other factors such as changes in body weight, waist size, and the amount of insulin needed daily. They will use devices that continuously monitor blood sugar levels to gather detailed information. The study aims to provide insights into how semaglutide can help manage blood sugar levels in people with “double diabetes” and improve their overall health. The study is expected to conclude in 2026.

The purpose of this research is to understand the long-term safety of teplizumab in young patients who have recently been diagnosed with Type 1 Diabetes Mellitus and who previously participated in an earlier study of this medication. The study will monitor these patients for an additional 42 months after their completion of the previous trial.

During the study, participants will receive teplizumab through an infusion into their veins. The medication will be given at a dose based on the patient’s body size. Throughout the study, doctors will monitor the participants’ health, including how well their body produces insulin and their blood sugar control. They will also track any side effects that may occur during or after the treatment.